Holen Sie sich die Stockscreener-App
16.50
1.69%
-0.30
Castle Biosciences Inc Aktie (CSTL) Neueste Nachrichten
Castle Biosciences, Revolution Medicines get FDA breakthrough statuses - MSN
Leerink Partnrs Has Pessimistic View of CSTL Q2 Earnings - Defense World
What drives Castle Biosciences Inc. stock priceRapidly expanding wealth - Autocar Professional
What analysts say about Castle Biosciences Inc. stockSkyrocketing investment returns - Autocar Professional
Castle Biosciences stock jumps after FDA grants Breakthrough Device status to melanoma test - MSN
Castle Bio, Revolution Medicines get FDA breakthrough statuses - Seeking Alpha
Castle Biosciences stock jumps after FDA grants Breakthrough Device status - Investing.com India
FDA Grants Breakthrough Status to Melanoma Test - Conexiant
FDA grants breakthrough device status to Castle Biosciences’ melanoma test - Investing.com Australia
FDA Grants Breakthrough Device Designation to Castle Biosciences’ DecisionDx®-Melanoma Test - GlobeNewswire
New York State Common Retirement Fund Has $3.27 Million Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Is Castle Biosciences Inc. a good long term investmentHigh-margin investment plays - jammulinksnews.com
Castle Biosciences Inc. Stock Analysis and ForecastTremendous financial leverage - jammulinksnews.com
Teacher Retirement System of Texas Grows Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Stephens Inc. AR Has $273,000 Stake in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences Achieves Multiple Awards Recognizing Workplace Excellence in 2025 Top Workplaces Program - Quiver Quantitative
Castle Biosciences earns multiple Top Workplaces awards, including national Healthcare Industry award. - AInvest
Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company’s Strong Culture - GlobeNewswire
Castle Biosciences Dominates Healthcare Workplace Rankings with 7 Major Awards and #3 Industry Position - Stock Titan
How Castle Biosciences Inc. stock performs during market volatilityTop Rated Trade Entries - Newser
Castle Biosciences, Inc. (NASDAQ:CSTL) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Castle Biosciences to Release Q2 2025 Financial Results and Host Conference Call on Aug. 4 - AInvest
Why Castle Biosciences Inc. stock attracts strong analyst attentionEarly Buy Suggestion - Newser
What makes Castle Biosciences Inc. stock price move sharplyProven Trading Plan - Newser
Castle Biosciences' Q2 Results: Diagnostic Innovation Fuels Growth Amid Profit Challenges - AInvest
Castle Biosciences, Inc. to Release Second Quarter Financial Results on August 4, 2025 - Nasdaq
Castle Biosciences to Release Second Quarter 2025 Financial - GlobeNewswire
Castle Biosciences Sets Q2 2025 Earnings Date: Key Financial Results Coming August 4 - Stock Titan
Allspring Global Investments Holdings LLC Raises Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences, Inc.(NasdaqGM: CSTL) dropped from Russell 2500 Growth Index - MarketScreener
Is Castle Biosciences (NASDAQ:CSTL) Using Too Much Debt? - 富途牛牛
GAMMA Investing LLC Purchases 4,142 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences partners with SciBase for diagnostic tests - MSN
Castle Biosciences Awards Major RSU Package: 135,978 Shares with 4-Year Vesting for Employee Retention - Stock Titan
Castle Biosciences Inc (CSTL) Stock Price Down 4.54% on Jun 17 - GuruFocus
Castle Biosciences partners with SciBase to develop atopic dermatitis test - Investing.com India
Castle Biosciences, SciBase Partner to Develop Predictive Tests for Skin Conditions - marketscreener.com
Castle Biosciences partners with SciBase for diagnostic tests (CSTL) - Seeking Alpha
Castle Biosciences partners with SciBase to develop atopic dermatitis test By Investing.com - Investing.com Nigeria
Castle Biosciences (CSTL) Partners with SciBase for Dermatology Advancements | CSTL Stock News - GuruFocus
Castle Biosciences enters collaboration, license agreement with Scibase to develop diagnostic tests for dermatologic diseases - MarketScreener
SciBase resolves on a directed share issue of SEK 19 million and announces its intention to carry out an additional directed share issue of approximately SEK 11 million - Yahoo Finance
Castle Biosciences Enters Collaboration and License Agreement wi - GuruFocus
SciBase signs license agreement with Castle Biosciences to develop dermatology diagnostic tests - marketscreener.com
Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases - The Manila Times
0.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):